Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer. Issue 6 (June 2015)

• Record Type: Journal Article
• Authors: Aziz, Atiqullah; Kempkensteffen, Carsten; May, Matthias; Lebentrau, Steffen; Burger, Maximilian; Chun, Felix K-H; Brookman-May, Sabine
• Is Part Of: Expert review of anticancer therapy. Volume 15:Issue 6(2015)
• Page Start: 649
• Page End: 666
• Publication Date: 2015-06
• Subjects: Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/14737140.2015.1038247
• Languages: English
• ISSNs: 1473-7140

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Several novel therapeutic agents have demonstrated improvement of overall survival and further patient relevant endpoints in the setting of castration-resistant prostate cancer. Nevertheless, two questions have become increasingly relevant: are there any prognostic or predictive markers that could ease clinical decision-making using risk stratification and risk-adapted treatment in order to provide a benefit for the patient? Furthermore, against the background of increasing possibilities of therapy sequencing in clinical practice and in the clinical trial landscape in castration-resistant prostate cancer, does an isolated evaluation of overall survival reliably mirror the benefit attributable to a single compound? To address both these questions, suitable parameters serving as surrogates for intermediate and long-term endpoints and reflecting individual benefit, respectively, need to be identified and proven.</p> </abstract>